Challenging Barriers to Community Oncology Care
Dipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.
The potential of new cancer therapies like chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody drug conjugates is exciting, but their accessibility remains a challenge. Many of these treatments are currently restricted to academic centers, leaving patients in local communities with fewer options.
At the American Society of Hematology 2023 Annual Meeting, Dipti Patel-Donnelly, MD, medical oncologist at Virginia Cancer Specialists, discussed challenges physicians and patients can face when treating hematologic malignancies in the community, as well as how to address these challenges through a co-management strategy.
Transcription:
0:09 |
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
